论文部分内容阅读
美国于1967年组建了真性红细胞增多症研究组(PVSG),其宗旨是使真性红细胞增多症(PV)的诊断标准化,并通过前瞻性随机临床观察确定PV的长期并发症。本病继发急性白血病(AL)的情况为研究重点之一,观察内容包括:1)单纯放血治疗PV时AL的发病率;2)~(32)P治疗PV时AL的发病率;3)应用瘤可宁治疗PV时AL的发病率,是否有其它既能控制PV症状又无致白血病作用的药物;4)有否临床和/或实验室指标可用以AL预测;5)PV发生AL是否为生存期延长的结果;6)骨髓髓样化生-骨髓纤维化的存在是否是发生AL的另一危险因素。
The United States established polycythemia vera (PVSG) in 1967 to standardize the diagnosis of polycythemia vera (PV) and to determine the long-term complications of PV by prospective, randomized clinical observation. The disease secondary to acute leukemia (AL) is one of the focuses of the study, the observations include: 1) the incidence of AL when bleeding alone PV; 2) the incidence of AL when PV is treated with 32 P; 3) 4, whether clinical and / or laboratory indicators are available for AL prediction, 5) whether PV occurs, whether AL is present or not, and if there is any other drug that controls both PV symptoms and leukemia. Is the result of prolonged survival; 6) Whether bone marrow myeloid metaplasia - myelofibrosis is another risk factor for the development of AL.